Nerve conduit with piezoelectric property and preparation method thereof
By using L-polylactic acid-L-polylysine nanofiber membranes and gelatin-L-polylactic acid membranes as nerve conduit structures, combined with electrospinning technology, the problems of insufficient mechanical properties and biocompatibility of existing nerve conduit materials have been solved, achieving the effect of promoting nerve differentiation and repair.
Patent Information
- Application Number
- CN202411048986.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-22
AI Technical Summary
Existing neural conduit materials have shortcomings in terms of mechanical properties and biocompatibility, and there is a lack of effective means to promote neural differentiation. In particular, there are no reports on the use of biodegradable materials in electrical stimulation and chemical induction.
A nerve conduit structure was prepared using a polylactic acid-polylysine nanofiber membrane as the inner layer, a gelatin-polylactic acid membrane as the middle layer, and a genipin membrane as the outer layer, combined with electrospinning technology. This structure possesses single orientation and piezoelectric properties, promoting nerve repair.
It achieves biocompatibility and biodegradability of nerve conduits, and promotes neural differentiation and repair through the synergistic effect of physical morphology, piezoelectric properties and chemical induction, providing good support and sustained drug release.
Smart Images

Figure CN118987339A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of medical materials and implantable medical devices, and in particular to a nerve conduit with piezoelectric properties and a preparation method thereof. Background Art
[0002] Traumatic nerve injury is a clinical problem worldwide. The long recovery time after nerve injury seriously affects the patient's physical and mental health. The "gold standard" for nerve injury repair is autologous nerve transplantation, but its clinical application is limited by the limited source of autologous nerves, the need to open a second surgical area, and the easy occurrence of secondary deformities and decreased sensation in the donor area after harvesting. In order to overcome these problems, the upsurge of tissue engineering artificial nerve research has brought new hope for the treatment of nerve injury.
[0003] The most critical factor in artificial nerve regeneration using tissue engineering methods is to obtain an ideal scaffold material. The scaffold material should at least meet the basic requirements for nerve cell growth: ① The scaffold has good biocompatibility; ② The scaffold can provide a microenvironment for nerve cell growth and adhesion; ③ The scaffold has good biodegradability.
[0004] Currently, commonly used nerve conduit (NGC) materials are mainly divided into two categories: biodegradable and non-biodegradable materials. The silicone nerve conduit reported in 1982 was the first NGC to be applied. However, silicone cannot be completely degraded and requires a second surgery to remove it. This problem can be overcome by using biodegradable materials. The most commonly used materials are natural polymers. One type of natural polymer is based on proteins, such as collagen, gelatin, thrombin and fibrinogen, and the other is based on polysaccharides, such as cellulose, chitin and chitosan. Natural polymers provide a biomimetic and cell-friendly environment, but have weak mechanical properties.
[0005] Poly-L-lysine (PLL) is a nerve growth factor that has a broad antibacterial spectrum, high safety, high temperature resistance, and can promote cell adhesion. At present, relevant research focuses on the following aspects: ① Promoting cell adhesion. Related studies have found that hydrophilic and positively charged material surfaces are more conducive to cell adsorption and growth. The PLL surface has more positive charges and adsorption with laminin is more conducive to cell spreading and growth; ② Good biocompatibility, can be used as an effective way to promote mRNA transport to the cell cytoplasm for transgenic expression; ③ It can inhibit the activity of lactococcal phages and has a certain antiviral effect. However, there are no reports on the addition of PLL to biomaterials at home and abroad, and the study of affecting neuroblast differentiation by affecting the physical morphology, piezoelectric properties and chemical induction of the material surface at the same time. Summary of the invention
[0006] The present invention provides a nerve conduit capable of simultaneously influencing neuroblast differentiation by influencing the physical morphology of the material surface, piezoelectric properties and chemical induction. The nerve conduit is in the shape of a hollow tube and comprises: An inner layer, and an intermediate layer and an outer layer successively covering the outer surface of the inner layer; The material of the inner layer is a L-polylactic acid (PLLA)-L-polylysine (PLL) nanofiber membrane; The inner surface of the inner layer has a single orientation; The material of the middle layer is gelatin-L-polylactic acid film; The material of the outer layer is genipin membrane.
[0007] The inner layer material of the nerve conduit of the present invention adopts a L-polylactic acid-L-polylysine nanofiber membrane with a single orientation (parallel morphology), which can simultaneously affect the differentiation of neurons through the characteristics of the surface parallel morphology (physical factor regulation) and L-polylysine (chemical factor regulation), and promote the process of nerve repair; and the genipin membrane as a shell material has toughness and can provide good support ability; the gelatin-L-polylactic acid membrane as an intermediate layer material can carry drugs and play a role in drug sustained release during the biodegradation process. Moreover, the nerve conduit prepared by the present invention has good biocompatibility and good biodegradability, which can effectively solve the problems caused by nerve transplantation and become an ideal substitute.
[0008] In addition, more importantly, the nerve guide of the present invention has piezoelectric properties. Current studies have shown that electrical stimulation can promote nerve growth. Therefore, the nerve guide of the present invention can further promote the nerve repair process by coordinating piezoelectric properties on the basis of the regulation of physical and chemical factors.
[0009] In the process of preparing the nerve conduit, the present invention screened the types of polylysine and found that L-polylysine can take into account good biocompatibility while not affecting the surface parallel morphology of the inner layer material. Other types of polylysine have relatively higher cytotoxicity and poor biocompatibility.
[0010] In some embodiments, the inner layer or the middle layer is prepared by electrospinning technology.
[0011] In some embodiments, the method for preparing the inner layer comprises: After L-polylactic acid and L-polylysine are dissolved in a solvent, a L-polylactic acid-L-polylysine nanofiber membrane with single orientation is prepared by electrospinning.
[0012] In some embodiments, the electrospinning parameters include: axle speed of 2000-8000 rpm; syringe propulsion speed of 0.01-0.08 mm / min; high pressure of 9 kv or more, and low pressure of 7 kv or less.
[0013] In some embodiments, the electrospinning parameters include: axle speed of 2600-3000 rpm; syringe propulsion speed of 0.03-0.04 mm / min; high pressure of 9-11 kv, and low pressure of 5-7 kv.
[0014] In some embodiments, in the electrospinning solution for preparing the nerve conduit, the concentration of the L-polylysine is 1-10 mg / mL; and / or the concentration of the L-polylactic acid is 0.05-0.1 g / mL.
[0015] Preferably, the concentration of the L-polylysine is 3-8 mg / mL.
[0016] The present invention further found that when the concentration of L-polylysine is controlled to be 3-8 mg / mL, the prepared L-polylactic acid-L-polylysine nanofiber membrane has the best effect of inducing neuroblast differentiation.
[0017] Most preferably, the concentration of the L-polylysine is 4-6 mg / mL.
[0018] In some embodiments, the solvent comprises trifluoroethanol, dichloromethane, or chloroform.
[0019] In some embodiments, poly-L-lysine is added to the poly-L-lactic acid solution by mixing with a magnetic stirrer.
[0020] In some embodiments, the electrospinning is an electrospinning technique using a high-speed spindle reception.
[0021] Preferably, the raw materials for preparing the inner layer include: 5-10 g of L-polylactic acid, 100-1000 mg of L-polylysine and 100 mL of solvent.
[0022] In some embodiments, the method for preparing the intermediate layer comprises: Gelatin was dissolved in L-poly(L-lactic acid) solution, and gelatin-L-poly(L-lactic acid) film was prepared by electrospinning.
[0023] In some embodiments, the method for preparing the outer layer comprises: soaking the catheter comprising the inner layer and the middle layer in a genipin solution.
[0024] In some embodiments, the method for preparing the nerve conduit comprises: (1) Using gelatin and poly (L-lactic acid) as raw materials, gelatin-poly (L-lactic acid) membrane was prepared by electrospinning technology; (2) using L-polylactic acid and L-polylysine as raw materials, preparing L-polylactic acid-L-polylysine nanofiber membrane on the surface of the gelatin-L-polylactic acid membrane prepared in step (1) by electrospinning technology to obtain a composite membrane; (3) Using a water-soluble material as an inner core, the composite membrane is wrapped around the outer surface of the inner core; the composite membrane is immersed in a genipin solution, and then washed with water until the water-soluble material is completely dissolved, thereby obtaining the nerve conduit.
[0025] Furthermore, the present invention provides the use of the nerve conduit or the preparation method in preparing nerve repair materials.
[0026] Compared with the prior art, the present invention has the following beneficial effects: The present invention provides a nerve conduit that can simultaneously affect neuroblast differentiation by affecting the physical morphology, piezoelectric properties and chemical induction of the material surface, and synergistically promote the adhesion, proliferation, migration ability and neuroblast differentiation of stem cells, thereby promoting the process of nerve repair; moreover, the nerve conduit prepared by the present invention has good biocompatibility and good biodegradability, can effectively solve the problems caused by nerve transplantation, and become an ideal substitute. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 are SEM images of parallel-morphology poly-L-lactic acid-poly-L-lysine nanofiber membranes loaded with different concentrations of PLL.
[0028] Figure 2 This is a statistical chart of the Br element content in the soaking solution detected by ICP-MS.
[0029] Figure 3 This is the result of the electrochemical workstation measuring the surface charge of different membrane materials.
[0030] Figure 4 This is a graph showing the results of a CCK-8 experiment to detect the effects of different membrane materials on the cell proliferation ability of bone marrow mesenchymal stem cells.
[0031] Figure 5 This is the result of immunofluorescence detection of the effect of different membrane materials on the expression of the nerve-related protein β-IIItubulin by bone marrow mesenchymal stem cells.
[0032] Figure 6 This is the result of RT-qPCR detection of the effects of different membrane materials on the expression of neural-related genes in bone marrow mesenchymal stem cells.
[0033] Figure 7 is a representation of the nerve conduit prepared in Example 3; wherein Figure 7 A is a schematic diagram of the structure of the nerve conduit. Figure 7 B is the length measurement diagram of the nerve conduit. Figure 7 C is the diameter measurement of the nerve conduit.
[0034] Figure 8 This is a gait analysis diagram of the repair of the sciatic nerve defect in rats; Figure 8 A is the sciatic function index result in gait analysis of rat sciatic nerve defect repair after injury. Figure 8 B is the tibial function index result in gait analysis of rat sciatic nerve defect repair. Figure 8 C is the result of the peroneal function index in the gait analysis of the repaired sciatic nerve defect in rats. Figure 8 D is the paw area result in gait analysis of rats with sciatic nerve defect repaired after injury, ns indicates not significant, *p<0.05, **p<0.01, ***p<0.001.
[0035] Fig. 9 This is the result of CCK-8 detection of the effect of episilon-PL on the proliferation ability of bone marrow mesenchymal stem cells.
[0036] Fig.10 This is the result of RT-qPCR detection of the effects of episilom-PL and PLL on hBMSCs neural-related genes. DETAILED DESCRIPTION
[0037] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0038] If no specific techniques or conditions are specified in the examples, all are carried out according to conventional methods or the techniques or conditions described in the literature in the field, or according to the product instructions. If no manufacturer is specified for the reagents and instruments used, all are conventional products that can be purchased through regular channels.
[0039] The formula of the neurogenic induction solution used in the following examples is as follows: Neurobasal A (Gibco, USA), B27 (Gibco, USA), 40 ng / mL FGF, and 20 ng / mL EGF.
[0040] Example 1
[0041] This embodiment provides a nerve conduit, and the preparation method is as follows: 1. Preparation of L-polylactic acid-L-polylysine nanofiber membrane
[0042] (1) Dissolve 7 g of L-polylactic acid in 100 mL of trifluoroethanol solution and stir thoroughly using a magnetic stirrer; (2) Weigh 100 mg of L-polylysine and add it to the stirred L-polylactic acid solution and stir for 4 h; (3) The solution is decompressed to eliminate bubbles; (4) The speed of the electrospinning receiver (high-speed wheel shaft) was set to 2800 rpm, the speed of the syringe was set to 0.034 mm / min, the high pressure was set to 10 kV, and the low pressure was set to 6 kV. Electrospinning was used to prepare L-polylactic acid-L-polylysine nanofiber membrane with parallel morphology.
[0043] 2. Nerve catheter preparation
[0044] (1) Dissolve 10 g of gelatin in 100 mL of 7% poly (L-lactic acid) (PLLA) solution and stir evenly using a magnetic stirrer; (2) The speed of the electrospinning receiver (high-speed wheel shaft) was set to 2800 rpm, the speed of the syringe was set to 0.034 mm / min, the high pressure was set to 10 kV, and the low pressure was set to 6 kV, and gelatin-L-lactic acid film was prepared by electrospinning; (3) After removing the gelatin-L-polylactic acid film, the film is divided into two parts at the middle of the width of the film; (4) re-fixing the half of the membrane on the surface of the electrospinning high-speed wheel shaft, and preparing the L-polylactic acid-L-polylysine nanofiber membrane thereon according to the method in step 1; (5) Using PVA water-soluble material as the inner core, wrapping the catheter around the left-handed polylactic acid-left-handed polylysine nanofiber membrane; (6) The catheter covered with the PVA water-soluble material was immersed in a 1.5% genipin solution for 30 min, and then washed with distilled water until the PVA water-soluble material was completely dissolved; after drying, the catheter was taken out to obtain a nerve catheter.
[0045] Example 2
[0046] This embodiment provides a nerve conduit, and the preparation method is different from that of embodiment 1 only in that: In step (2) of step 1, the amount of L-polylysine is adjusted to 250 mg.
[0047] Example 3
[0048] This embodiment provides a nerve conduit, and the preparation method is different from that of embodiment 1 only in that: In step (2) of step 1, the amount of L-polylysine is adjusted to 500 mg.
[0049] Example 4
[0050] This embodiment provides a nerve conduit, and the preparation method is different from that of embodiment 1 only in that: In step (2) of step 1, the amount of L-polylysine is adjusted to 1000 mg.
[0051] Test Example 1
[0052] In this test example, materials science characterization was performed on the L-polylactic acid-L-polylysine nanofiber membrane with parallel morphology prepared in the above example.
[0053] The surface morphology of parallel-morphology poly (L-lactic acid)-poly (L-lysine) nanofiber membranes loaded with different concentrations of PLL and smooth PLLA membrane (control) were detected by scanning electron microscopy (SEM), and the surface element distribution and spinning diameter were statistically analyzed.
[0054] The results are as follows Figure 1 As shown, the surface spinning of the L-polylactic acid-L-polylysine nanofiber membrane in each embodiment is relatively uniform, and the spinning direction tends to be consistent; the addition of PLL does not affect the surface morphology, and the characteristic Br element in PLL is evenly distributed on the material surface; the smooth membrane surface is clean, and the material morphology is relatively uniform.
[0055] Furthermore, in order to study the release characteristics of PLL in the parallel morphology of L-PLA-PLA nanofiber membrane, the L-PLA-PLA nanofiber membrane of Example 3 was immersed in PBS, and the content of Br element in the immersion solution was detected by ICP-MS. The results are as follows: Figure 2 As shown, as time goes by, the Br element stably exists in the immersion solution, which proves that the poly (L-lactic acid)-poly (L-lysine) nanofiber membrane has sustained release ability.
[0056] Furthermore, the surface charge of the L-polylactic acid-L-polylysine nanofiber membrane of Example 3 was measured using an electrochemical workstation, and the energy collection characteristics of different samples with metal copper foil as upper and lower electrodes (sealed with a moisture-proof bag) under periodic compression force were measured using a linear motor. The output voltage was recorded by a Keithley electronic measuring instrument (DM6500).
[0057] The results are as follows Figure 3 As shown, after adding PLL into the parallel morphology PLLA film, the surface piezoelectric properties of L-polylactic acid-L-polylysine nanofiber membrane (PLL-PLLA) were significantly enhanced.
[0058] Test Example 2
[0059] In this test example, CCK-8 was used to detect the effect of L-polylactic acid-L-polylysine nanofiber membranes loaded with different concentrations of PLL on cell activity. The Control group was the control group, the Flat+N group was a smooth PLLA membrane treated with a neural induction solution, and the Align group was a parallel morphology PLLA membrane without adding PLL. The CCK-8 experiment was performed according to the CCK-8 experimental instructions of Japan Tongren Company, and the detection steps were as follows: (1) First, the membrane materials of different experimental groups were cut into the same size and placed in a 96-well cell culture plate. After sterilization, hBMSCs were evenly inoculated into the 96-well cell culture plate using a spray gun for culture. Subsequently, a 10% concentration of CCK-8 working solution was prepared. (2) After preheating PBS, discard the culture medium in the 96-well plate and wash once with PBS; (3) Discard the PBS in the well plate, add 10% CCK-8 working solution, and then place the 96-well plate in an incubator and incubate for 2 hours; (4) Use an ELISA reader to measure the optical density (OD) value of each well at a wavelength of 450 nm.
[0060] The experimental results are as follows Figure 4 As shown, the results showed that the ability of the neurogenic induction fluid group (Flat+N group) to induce cell proliferation was weaker; PLL concentration had a certain promoting effect on cell proliferation, among which the 5 mg / mL group had the strongest ability to promote cell proliferation.
[0061] Test Example 3
[0062] In this test example, immunofluorescence, RT-qPCR and Western Blot were used to detect the expression of neurogenic related genes and proteins in cells induced by the poly-L-lactic acid-poly-L-lysine nanofiber membrane prepared in the above example.
[0063] 1. Immunofluorescence was used to detect the effect of different concentrations of PLL on the expression of neural-related proteins (β-III tubulin) in hBMSCs cells. The immunofluorescence steps are as follows: hBMSCs were seeded onto the surface of the membrane materials of each experimental group, and the samples were fixed with 4% paraformaldehyde, and β-IIItubulin, cytoskeleton and nucleus staining were performed. The expression of neuroblastoma-related protein β-IIItubulin and cytoskeleton morphology in the cells were observed using an inverted fluorescence microscope. The specific operation steps are as follows: (1) hBMSCs were seeded onto the surface of a smooth PLLA membrane, a parallel PLLA membrane, and a poly-L-lactic acid-poly-L-lysine nanofiber membrane of each embodiment; hBMSCs were seeded onto the surface of a smooth PLLA membrane and then treated with a neurogenic induction solution as a positive control group; (2) Discard the culture medium and preheat PBS in a 37°C incubator. Then, wash the plate once with PBS and fix the cells with 4% paraformaldehyde. Fix the cells for 15 minutes at room temperature. (3) After removing the fixative, wash the cells three times with preheated PBS solution, each time for 10 min; (4) Add 1 ml of 0.5% Triton X-100 solution to each well for 5 minutes, discard the Triton X-100 solution, and wash the cells three times with preheated PBS solution, each time for 10 minutes; (5) Block with immunofluorescence blocking solution for 10 min; (6) Incubate the samples with 1% BSA (1:500) anti-β-III tubulin primary antibody (rabbit) and store in a 4°C refrigerator overnight; (7) Wash the cells three times with PBS solution, 10 min each time; (8) Prepare 1:200 goat anti-rabbit IgG H&L (Alexa Fluor® 488) in 1% BSA, incubate the sample at room temperature for 1 h 40 min in the dark, and wash the sample three times with PBS solution, each time for 10 min; (9) Prepare 100 nM phalloidin working solution using 1% BSA, add 1 ml of phalloidin staining solution to each well and incubate at room temperature in the dark for 40 min. Wash the cells three times with preheated PBS solution, each time for 5 min. (10) Incubate the cells with 1 mL of ready-to-use DAPI solution at room temperature in the dark for 30 min. Wash the cells three times with preheated PBS solution, each time for 10 min. (11) Discard the PBS in the bottle cap, take out the membrane material fixed in the bottle cap, cut it off and place it on a tissue slide; (12) The slides were sealed with anti-fluorescence attenuation sealing agent, and the morphology of cells and cytoskeleton on the surface of the membrane material were observed under an inverted phase contrast fluorescence microscope.
[0064] The experimental results are as follows Figure 5As shown in the results, it was found that the addition of PLL enhanced the expression of β-III tubulin in hBMSCs cells, and its expression level was the highest when the concentration of PLL was 5 mg / mL, even higher than the positive control group added with neural induction solution. The expression of β-III tubulin in hBMSCs induced by excessively high doses (10 mg / mL) of PLL was still higher than that of the control group (Flat).
[0065] 2. β-III tubulin is an early neuronal marker for axonal recovery; MAP2 is a marker for late neurogenic differentiation; NSE is a characteristic olefinic alcohol in the process of neurogenic differentiation. RT-qPCR was used to detect the expression of neurogenic related genes (β-III tubulin, MAP2, NSE) after hBMSCs were treated with L-polylactic acid-L-polylysine nanofiber membranes with different concentrations of PLL. The RT-qPCR steps are as follows: (1) Extract total RNA from induced cells using Trizol
[0066] hBMSCs were inoculated onto the surface of the membrane materials of each experimental group. After hBMSCs were inoculated onto the surface of the smooth PLLA membrane, they were treated with neural induction solution as the positive control group. The culture medium was discarded and the cells were rinsed with PBS three times. 1 mL of Trizol reagent was added to each sample well, and the cells on the surface of the membrane materials of each experimental group were scraped with a cell scraper and allowed to stand for 5 min. The Trizol reagent containing cells was collected and transferred to a 1.5 mL EP tube. 200 μL of chloroform solution was added to each EP tube, and the tube was mixed upside down until the solution turned milky white and pink, and allowed to stand for 10 min. The EP tubes collected from each group were placed in a low-temperature refrigerated centrifuge and centrifuged at 4°C and 12,000 rpm for 15 min. The EP tube was removed from the centrifuge, and the supernatant in the EP tube was carefully aspirated. Be careful not to aspirate the white precipitate in the middle. About 300 μL of supernatant can be aspirated and transferred to a new EP tube, and then 0.5-1 times of isopropanol was added, and the tube was repeatedly mixed upside down and allowed to stand at room temperature for 10 min. The refrigerated centrifuge was set at 4°C and 12,000 rpm. Centrifuge for 10 minutes; carefully discard the supernatant, and be careful to retain the white precipitate at the bottom of the EP tube; add 1 ml of 75% ethanol solution, wash the white precipitate at the bottom of the EP tube by turning it upside down, set the refrigerated centrifuge at 4°C, centrifuge at 7500 rpm for 5 minutes, and repeat twice; carefully discard the supernatant, use a refrigerated centrifuge to instantly spin the EP tube, use a 10μL pipette to remove the remaining 75% ethanol at the bottom of the EP tube, after the ethanol is completely evaporated, the white precipitate at the bottom of the EP tube gradually turns into a transparent watermark; after the precipitate turns into a watermark, add about 10μL of DEPC water to each EP tube to completely dissolve the precipitated RNA at the bottom of the EP tube; use an ultra-micro spectrophotometer (NanoDrop 2000) to detect the concentration of RNA samples in each EP tube.
[0067] (2) Reverse transcription PCR reaction
[0068] Determine the RNA concentration in each group of samples and calculate the RNA volume required for 1000ng RNA; prepare the reverse transcription reagent working solution: gDNA Eraser 1μL, 5*gDNA Eraser Buffer 2μL, Total RNA 1000ng, add RNase FreedH2O to balance the working solution to 10μL. Then centrifuge the reverse transcription reagent working solution for 30s, set the reverse transcription PCR program: 37℃ 15min for reverse transcription reaction, heat to 85℃ 5s to inactivate reverse transcriptase, obtain reverse transcribed cDNA, and then seal each group of cDNA and store it at -20℃.
[0069] (3) RT-qPCR experiment
[0070] Using the cDNA obtained by reverse transcription as a template, real-time fluorescence quantitative PCR was performed to detect neurogenic genes. The reaction reagents were: SYBR® Green Master (2*) 10μL, PCR Forward Primer (10μM) 0.5μL, PCR Reverse Primer (10μM) 0.5μL, cDNA 1μL, DEPC water 8μL. The primer sequences are shown in Table 1; the total volume of the real-time fluorescence quantitative PCR reagent mixture of each group of samples was 20μL, and the real-time fluorescence quantitative PCR reaction conditions were set as follows: 95℃10min, 60℃ 60s, 40 cycles, and a melting curve program was added later. The corresponding sample CT value was obtained, and then the relative mRNA expression of neurogenic genes was calculated using the △△⊿⊿CT method, and a bar graph was drawn for statistical analysis.
[0071] The experimental results are as follows Figure 6 As shown in the figure, the expression of β-III tubulin and MAP2 in each group increased with time. Among them, the expression of β-III tubulin was most significantly different between the poly-L-lactic acid-L-polylysine nanofiber membrane group and the smooth PLLA membrane at 14 days. The expression of MAP2 increased with time, and the difference between the poly-L-lactic acid-L-polylysine nanofiber membrane group and the smooth PLLA membrane was most significant at 21 days.
[0072] In summary, the addition of PLL enhanced the expression of neurogenic genes in hBMSCs cells, and the expression level was the highest when the concentration of PLL was 5 mg / mL, even higher than the positive control group added with neurogenic induction solution (P<0.05, ** P<0.01, *** P<0.001).
[0073] Table 1
[0074] The above experimental results show that the surface of the L-polylactic acid-L-polylysine nanofiber membrane prepared in the embodiment of the present invention is spun evenly and in a consistent direction; it has good biocompatibility and can promote the adhesion, proliferation and migration ability of hBMSCs in a certain time and dose dependence, and can induce hBMSCs to differentiate into neurons.
[0075] Test Example 4
[0076] This test example uses animal experiments to test the repair effect of the nerve conduit in Example 3 on sciatic nerve defect damage in rats. The experimental steps are as follows: 1. Rat bone marrow mesenchymal stem cells (rBMSCs) were cultured on the inner surface of the nerve conduit prepared in Example 3 for 14 days to prepare a stem cell-based nerve conduit.
[0077] 2. Preparation of SD rat sciatic nerve defect and repair model
[0078] (1) Purchase and breeding of SD rats
[0079] Six-week-old mice purchased from Spafford were placed in fixed cages and adapted for 10 days in a constant temperature and humidity environment. A maximum of three rats can be kept in each cage. To ensure that the cage environment is suitable for rat survival, the air temperature, humidity, and ventilation of the laboratory animal room are kept normal as much as possible, and the day and night alternation is normal to ensure the normal biological rhythm of the rats. Six hours before surgery, the rats were fasted and deprived of water. In the process of constructing the sciatic nerve defect injury model of SD rats, all operations were carried out strictly in accordance with the specifications, and all protocols involving the use of animals followed the ethical guidelines of the Animal Ethics Committee of Capital Medical University and were approved by the Animal Ethics Committee of Beijing Stomatological Hospital Affiliated to Capital Medical University.
[0080] (2) Experimental animal grouping
[0081] Eight-week-old female SD rats were divided into autologous nerve transplantation group, sham operation group, stem cell-derived nerve conduit group (PLL-PLLA-rBMSCs) and axotomy group, with 6 rats in each group. (3) Surgical procedure for constructing sciatic nerve defect in SD rats
[0082] ① We anesthetized the rats with isoflurane and a matching gas anesthesia machine, shaved the hair and prepared the skin from the outer side of the hind thigh to the femur, and disinfected it with iodine; ② Place the animal in a prone position and fix the limbs on the surgical board. After disinfecting the surgical area with alcohol cotton balls, cut the skin of the left thigh about 1.5 cm; use hemostatic forceps to bluntly separate the biceps femoris along the muscle line to expose the sciatic nerve. Use the fixation hook to slightly open the muscle to expose the surgical field, and use forceps to gently separate the sciatic nerve. Free the nerve about 7 mm in the main trunk before the trifurcated branch of the sciatic nerve to create a 5 mm sciatic nerve defect; ③ The anastomosis method between the cannula and the nerve stump is microanastomosis technology: 8 / 0 medical non-destructive absorbable sutures are used to insert the nerve stump into the nerve cannula. The insertion length of each end depends on the distance from the needle entry point to the tube opening. Generally, it is set to 1mm, that is, the nerve stump is inserted into the nerve catheter by 1mm. ④ Autologous nerve anastomosis method: After the nerve is freed, use microscissors to obtain the nerve trunk with a length of about 5 mm, and use microsuturing technology to flip the nerve trunk about 180° for suturing; ⑤ Except for the sham operation group where only the muscular layer was opened for suture, the muscular layer of each nerve transection group was carefully sutured after anastomosis to avoid displacement of the implanted material, and the skin was sutured. Blood stains were wiped off with saline, and penicillin was injected after disinfection with iodine.
[0083] ⑥ Each group of SD rats were placed in a 37℃ constant temperature small animal resuscitation machine to prevent hypothermia in rats after surgery, and then placed in a feeding box after the SD rats fully woke up. 105 units of penicillin were injected intramuscularly within one week after surgery to prevent wound infection and relieve rat neuropathic pain; the overall condition and wound condition of the SD rats were closely observed.
[0084] (4) Rat gait analysis
[0085] 16 weeks after surgery, we performed gait analysis (rodent gait analysis system, DigiGait) on rats in each group, and measured the sciatic functional index (SFI), tibial functional index (TFI), and fibula functional index (PFI). For specific test methods, refer to the manufacturer's instructions. SFI, TFI, and PFI are negative numbers between 0 and -100. These indices are coefficients obtained by measuring the walking trajectory of rats with nerve defects. They are calculated by equations for multiple linear regression analysis to provide a non-invasive, quantitative assessment of the hindlimb motor function of rats with selective hindlimb nerve defects. Among them, SFI needs to be obtained after gait analysis measurement, and the formula is as follows:
[0086] Among them, IT represents the distance between the second and fourth toes; TS represents the distance between the first and fifth toes; PL represents the distance from the heel to the top of the third toe. NPL, NTS and NIT represent the PL, TS and IT values of the hind limb on the non-operated side, respectively. EPL, ETS, EIT represent the PL, TS and IT values of the operated side of the experimental animals. Paw area variability records the standard deviation of the paw area in the stride set. The paw area of healthy animals in contact walking is a regular step-by-step form. When the animal recovers from the injury, this value gradually approaches 0. The experiment was repeated 3 times for each rat.
[0087] The experimental results are as follows: The schematic diagram of the structure of the nerve conduit prepared in Example 3 is as follows Figure 7 As shown in A, Figure 7 B is a length measurement diagram of the nerve conduit prepared in Example 3, Figure 7C is a diameter measurement diagram of the nerve conduit prepared in Example 3.
[0088] The sciatic nerve function index (SFI) is a quantitative method to evaluate motor function after sciatic nerve defect injury. It evaluates the muscle function innervated by the sciatic nerve by analyzing the distribution of toes. The gait analysis results showed that the sciatic nerve function index (SFI) of rats in the stem cell nerve conduit group ( Figure 8 A), Tibial Function Index (TFI) ( Figure 8 B), Peroneal Function Index (PFI) ( Figure 8 C) showed significant recovery, but still inferior to the sham operation group; it is worth noting that the plantar contact area of rats in the stem cell nerve conduit group was significantly restored, much better than the disconnection group and even close to the sham operation group ( Figure 8 D).
[0089] Comparative Example
[0090] This comparative example compares the types of lysine used in preparing nerve conduits to screen out the types of lysine with good biosafety.
[0091] 1. Episilon-Lysine (episilon-PL) Preparation
[0092] Prepare episilon-PL solution with a concentration of 1 mg / mL, that is, accurately weigh episilon-PL powder and fully dissolve it in the culture medium, then filter the solution with a 0.22 μm filter to remove impurities. Take 1 μL of episilon-PL induction solution with a concentration of 1 mg / mL and add it to 1 mL of complete culture medium to obtain episilon-PL induction solution with a concentration of 1 μg / mL, and obtain episilon-PL induction solutions of different concentrations by multiple dilution.
[0093] 2. CCK-8 assay to detect cytotoxicity
[0094] hBMSCs were uniformly inoculated into a 96-well cell culture plate using a spray gun, and the cells were cultured in culture media containing the above-mentioned episilon-PL induction solution at different concentrations. During this period, the cell proliferation ability was determined by the CCK-8 method.
[0095] The results are as follows Fig. 9As shown in the data, when the concentration of episilon-PL after dilution was higher than 10^-8, the inhibition of hBMSCs cell proliferation was more obvious compared with the normal culture medium group (concentration was 0); among them, when the concentration of episilon-PL was higher than 10^-3, the toxicity to cell proliferation was very significant; the inhibitory effect of episilon-PL on cell proliferation gradually increased with the increase of concentration, showing a dose-dependent manner, and the difference was statistically significant (P<0.001).
[0096] 3. RT-qPCR detection of the effects of episilom-PL and PLL on hBMSCs neural-related genes
[0097] hBMSCs were inoculated into culture medium containing different concentrations of PLL and episilom-PL. After culture, total RNA of induced cells was extracted using Trizol, and cDNA was obtained by reverse transcription. Then, the cDNA obtained by reverse transcription was used as a template to detect the neurogenic gene β-III tubulin by real-time fluorescence quantitative PCR. The reaction reagents were: SYBR® Green Master (2*) 10μL, PCR Forward Primer (10μM) 0.5μL, PCR Reverse Primer (10μM) 0.5μL, cDNA 1μL, DEPC water 8μL. The upstream primer sequence of β-III tubulin was AGGTGCGTGAGGAGTATCCC, and the downstream primer sequence was CATCCGTGTTCTCCACCAGC. The total volume of the real-time fluorescence quantitative PCR reagent mixture of each group of samples was 20μL, and the real-time fluorescence quantitative PCR reaction conditions were set as follows: 95℃ 10min, 60℃ 60s, 40 cycles, and a melting curve program was added later. The corresponding sample CT values were obtained, and then the relative mRNA expression of the neurogenic-related gene β-III tubulin was calculated using the △△CT method, and a bar graph was drawn for statistical analysis.
[0098] Test results such as Fig.10 As shown, after adding different concentrations of PLL and episilom-PL to each group of cells, PLL can significantly increase the expression of β-III tubulin compared with the episilom-PL group, and L-polylysine (PLL) has better cell biocompatibility and weaker cytotoxicity.
[0099] Therefore, the present invention selects L-poly-lysine which has good biological safety and good effect of promoting the expression of hBMSCs neural related genes to prepare the inner layer of the nerve conduit.
[0100] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A nerve conduit, which is a hollow tube, characterized in that: include: An inner layer, and an intermediate layer and an outer layer successively covering the outer surface of the inner layer; The material of the inner layer is L-polylactic acid-L-polylysine nanofiber membrane; The inner surface of the inner layer has a single orientation; The material of the middle layer is gelatin-L-polylactic acid film; The material of the outer layer is genipin membrane.
2. The nerve guide according to claim 1, characterized in that The inner layer or the middle layer is prepared by electrospinning technology.
3. The nerve guide according to claim 2, characterized in that The preparation method of the inner layer comprises: After L-polylactic acid and L-polylysine are dissolved in a solvent, a L-polylactic acid-L-polylysine nanofiber membrane with single orientation is prepared by electrospinning.
4. The nerve guide according to claim 2, characterized in that: The preparation method of the intermediate layer comprises: Gelatin was dissolved in L-poly(L-lactic acid) solution, and gelatin-L-poly(L-lactic acid) film was prepared by electrospinning.
5. The nerve guide according to claim 3 or 4, characterized in that: The parameters of the electrospinning include: the wheel shaft speed is 2000-8000 rpm; the syringe propulsion speed is 0.01-0.08 mm / min; the high pressure is above 9 kv and the low pressure is below 7 kv.
6. The nerve guide according to claim 3, characterized in that: In the electrospinning solution for preparing the nerve conduit, the concentration of L-polylysine is 1-10 mg / mL; and / or the concentration of L-polylactic acid is 0.05-0.1 g / mL.
7. The nerve guide according to claim 1, characterized in that: The method for preparing the outer layer comprises: soaking the catheter containing the inner layer and the middle layer in a genipin solution.
8. The nerve guide according to claim 1, characterized in that: The nerve guide has piezoelectric properties.
9. The method for preparing a nerve conduit according to any one of claims 1 to 8, characterized in that: include: (1) Using gelatin and poly (L-lactic acid) as raw materials, gelatin-poly (L-lactic acid) membrane was prepared by electrospinning technology; (2) using L-polylactic acid and L-polylysine as raw materials, preparing L-polylactic acid-L-polylysine nanofiber membrane on the surface of the gelatin-L-polylactic acid membrane prepared in step (1) by electrospinning technology to obtain a composite membrane; (3) Using a water-soluble material as an inner core, the composite membrane is wrapped around the outer surface of the inner core; the composite membrane is immersed in a genipin solution, and then washed with water until the water-soluble material is completely dissolved, thereby obtaining the nerve conduit.
10. Use of the nerve conduit according to any one of claims 1 to 8 or the preparation method according to claim 9 in preparing nerve repair materials.
